PPARG and ovarian carcinoma: They activate PPARγ in transactivation assays, and CDDO-induced apoptosis was diminished by dominant-negative PPARγ in myeloid HL-60 cells and by T007 in myeloid U937 cells [68], but CDDO-Im-induced differentiation in leukemia cells was not inhibited by the PPARγ antagonist GW9662 [61], and T007 did not affect inhibition of SKOV3 ovarian cancer cell growth by CDDO [69].